Trial completion • Enrollment change • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • FGFR (Fibroblast Growth Factor Receptor)
|
EGFR mutation • IDH1 mutation • ALK rearrangement • FGFR mutation
|
pimivalimab (JTX-4014) • polzastobart (JTX-8064)